Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

CRCA vs BMNU: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CRCA Wins Head-to-Head Institutional Verdict (0–0 across 6 Pillars · 2–1 Matrix Metrics)

CRCA Overall Winner 6-Pillar Tally: CRCA 0 – 0 BMNU (6 Tie) Matrix Metrics: CRCA 2 – 1 BMNU

As of Nov 16, 2026, ProShares Ultra CRCL (CRCA) is the stronger overall head-to-head candidate over T-REX 2X Long BMNR Daily Target ETF (BMNU) in the Tradestie Institutional Equity Comparison Engine, winning 2–1 core matrix metrics and 0–0 across our 6-pillar institutional scorecard (led by composite factor balance). CRCA carries a Unified Composite Score of 51.0/100 (HOLD) at $7.83 (N/M Forward P/E, N/A operating margin), whereas BMNU carries 49.7/100 (HOLD) at $7.17 (N/M Forward P/E, N/A operating margin).

  • Technical & Structure Timing Caution: CRCA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 29.0); meanwhile BMNU is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CRCA vs BMNU
CRCA NYSE Arca Head-to-Head Winner
ProShares Ultra CRCL
Institutional Equity
$7.83
-14.56% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 4.88β · 137% Vol
Unified Composite Score
51.0 / 100 HOLD
Tech 53.0 Fund 54.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -13.9%), weak momentum, RSI 29
RSI-14: 29.0 · SMA20: $13.70 · SMA50: $17.28
BMNU Cboe BZX
T-REX 2X Long BMNR Daily Target ETF
Institutional Equity
$7.17
-12.92% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.38β · 164% Vol
Unified Composite Score
49.7 / 100 HOLD
Tech 38.0 Fund 57.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.9%), weak momentum, RSI 32
RSI-14: 31.9 · SMA20: $11.58 · SMA50: $16.11

6-Pillar Scorecard Institutional Category Breakdown (CRCA 0 – 0 BMNU)

Columns: Metric · CRCA · BMNU
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale Tie
Revenue Growth (YoY) N/A N/A
Earnings Growth (YoY) N/A N/A
TTM Revenue (USD) N/A N/A
Market Cap N/A N/A
3. Profitability & Quality Tie
Gross Margin N/A N/A
Operating Margin N/A N/A
Net Profit Margin N/A N/A
Return on Equity (ROE) N/A N/A
4. Balance Sheet & Cash Flow Tie
Cash Generation (TTM) N/A N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 141.9% (<1st %ile) 253.8% (100th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CRCA (2) vs BMNU (1)
Institutional Metric CRCA BMNU Criterion Row Edge
Market Capitalization
Scale
N/A N/A Larger Scale Tie
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A N/A Higher Growth Tie
Operating Margin (TTM)
Profitability
N/A N/A Higher Margin Tie
Net Profit Margin
Profitability
N/A N/A Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
N/A N/A Higher ROE Tie
52-Week Range Position
Momentum
7% ($1–$93) 27% ($1–$25) Stronger Trend BMNU
Beta / 30D Volatility
Risk Regime
4.88β · 137% Vol 1.38β · 164% Vol Lower Realized Risk CRCA
Unified Institutional Score
Composite Signal
51.0 / 100 (HOLD) 49.7 / 100 (HOLD) Higher Composite CRCA
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon BMNU +6.75 pp
CRCA: -53.64% · BMNU: -46.89%
3M Horizon BMNU +12.27 pp
CRCA: -48.32% · BMNU: -36.05%
6M Horizon BMNU +480.11 pp
CRCA: -83.57% · BMNU: +396.54%
1Y Horizon CRCA +96.7 pp
CRCA: +60.88% · BMNU: -35.82%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CRCA vs BMNU. Trailing 12-month operating profitability (CRCA N/A vs BMNU N/A) and valuation multiples (CRCA N/M vs BMNU N/M Forward P/E) are benchmarked directly in Pillar 4 below.

CRCA ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
BMNU ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CRCA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 141.9%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CRCA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BMNU UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 253.8%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BMNU Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CRCA Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
BMNU Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CRCA vs BMNU Key Questions & Quantitative Answers

As of Nov 16, 2026, ProShares Ultra CRCL (CRCA) is the stronger overall head-to-head candidate over T-REX 2X Long BMNR Daily Target ETF (BMNU) in the Tradestie Institutional Equity Comparison Engine, winning 2–1 core matrix metrics and 0–0 across our 6-pillar institutional scorecard (led by composite factor balance). CRCA carries a Unified Composite Score of 51.0/100 (HOLD) at $7.83 (N/M Forward P/E, N/A operating margin), whereas BMNU carries 49.7/100 (HOLD) at $7.17 (N/M Forward P/E, N/A operating margin). Technical & Structure Timing Caution: CRCA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 29.0); meanwhile BMNU is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CRCA and BMNU split Growth & Scale metrics: CRCA posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with BMNU at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, CRCA generates N/A in USD-normalized revenue versus N/A for BMNU. In operating R&D and SG&A reinvestment, CRCA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for BMNU.

CRCA and BMNU trade at balanced relative valuation multiples. CRCA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas BMNU trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CRCA (N/A ROE) versus BMNU (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, CRCA carries 141.9% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (4.88β · 137% Vol realized risk). By comparison, BMNU carries 253.8% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.38β · 164% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.